176
Views
19
CrossRef citations to date
0
Altmetric
Research Article

Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors

, , , , , , , & show all
Pages 579-596 | Received 21 Aug 2007, Accepted 17 Mar 2008, Published online: 07 Nov 2008

References

  • J Bartek, and J. Lukas. (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421–429.
  • B Booth, and R. Zemmel. (2004). Opinion/outlook: prospects for productivity. Nature Reviews Drug Discovery 3:451–456.
  • EC Busby, DF Leistritz, RT Abraham, LM Karnitz, and JN. Sarkaria. (2000). The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Research 60:2108–2112.
  • Z Chen, Z Xiao, J Chen, SC Ng, T Sowin, H Sham, S Rosenberg, S Fesik, and H. Zhang. (2003). Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Molecular Cancer Therapeutics 2:543–548.
  • Z Chen, Z Xiao, WZ Gu, J Xue, MH Bui, P Kovar, G Li, G Wang, ZF Tao, Y Tong, NH Lin, HL Sham, JY Wang, TJ Sowin, SH Rosenberg, and H. Zhang. (2006). Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. International Journal of Cancer 119:2784–2794.
  • A Eastman, EA Kohn, MK Brown, J Rathman, M Livingstone, DH Blank, and GW. Gribble. (2002). A novel indolocarbazole, ICP-1, abrogates DNA damage-induced cell cycle arrest and enhances cytotoxicity: similarities and differences to the cell cycle checkpoint abrogator UCN-01. Molecular Cancer Therapeutics 1:1067–1078.
  • RC III Edmunds, PC Ma, and CP. Tanio. (2001). Splicing a cost squeeze into the genomics revolution. McKinsey Quarterly 2:15–18.
  • SW. Fesik. (2000). Insights into programmed cell death through structural biology. Cell 103:273–282.
  • R Frank, and R. Hargreaves. (2003). Clinical biomarkers in drug discovery and development. Nature Reviews Drug Discovery 2:566–580.
  • JH Hendry, and CM. West. (1997). Apoptosis and mitotic cell death: their relative contributions to normal-tissue and tumor radiation response. International Journal of Radiation Biology 71:709–719.
  • DG Johnson, and CL. Walker. (1999). Cyclins and cell cycle checkpoints. Annual Review of Pharmacology and Toxicology 39:295–312.
  • K Koniaras, AR Cuddihy, H Christopoulos, A Hogg, and MJ. O'Connell. (2001). Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20:7453–7463.
  • G Pascreau, Y Arlot-Bonnemains, and C. Prigent. (2003). Phosphorylation of histone and histone-like proteins by aurora kinases during mitosis. Progress in Cell Cycle Research 5:369–374.
  • C Prigent, and S. Dimitrov. (2003). Phosphorylation of serine 10 in histone H3, what for?. Journal of Cell Science 116:3677–3685.
  • IB Roninson, EV Broude, and BD. Chang. (2001). If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resistance Updates 4:303–313.
  • A Strasser, L O'Connor, and VM. Dixit. (2000). Apoptosis signaling. Annual Review of Biochemistry 69:217–245.
  • NC. Walworth. (2000). Cell-cycle checkpoint kinases: checking in on the cell cycle. Current Opinion in Cell Biology 12:697–704.
  • L Wang, GM Sullivan, LA Hexamer, LA Hasvold, R Thalji, M Przytulinska, ZF Tao, G Li, Z Chen, Z Xiao, and WZ Gu.
  • A Wang, N Yoshimi, N Ino, T Tanaka, and H. Mori. (1997). Overexpression of cyclin B1 in human colorectal cancers. Journal of Cancer Research & Clinical Oncology 123:124–127.
  • Z Xiao, Z Chen, AH Gunasekera, TJ Sowin, SH Rosenberg, S Fesik, and H. Zhang. (2003). Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. Journal of Biological Chemistry 278:21767–21773.
  • Z Xiao, J Xue, T Sowin, S Rosenberg, and H. Zhang. (2004). A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 24:1403–1411.
  • H Zhao, JL Watkins, and H. Piwnica-Worms. (2002). Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proceedings of the National Academy of Sciences U S A 99:14795–14800.
  • BB Zhou, and J. Bartek. (2004). Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nature Reviews Cancer 4:216–225.
  • BB Zhou, and EA. Sausville. (2003). Drug discovery targeting Chk1 and Chk2 kinases. Progress in Cell Cycle Research 5:413–421.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.